Author pages are created from data sourced from our academic publisher partnerships and public sources.
Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study.
OBJECTIVE Self monitoring of blood glucose (SMBG) in type 2 diabetes is a topic of current interest (imbalance between increased health-care costs and improvement in compliance with treatment and… Expand
Maternally Inherited Diabetes and Deafness: A Multicenter Study
Mitochondrial (mt) gene abnormalities cause disease due to defects in oxidative production of energy (1). In 1990, Goto and colleagues (2) described the co-segregation of a syndrome called… Expand
Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
- M. Nauck, R. Weinstock, G. Umpierrez, B. Guerci, Z. Skrivanek, Z. Milicevic
- Diabetes Care
- 12 July 2014
OBJECTIVE To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in uncontrolled, metformin-treated patients with type… Expand
Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence
- M. Caron, M. Auclair, +8 authors C. Vigouroux
- Medicine, Biology
- Cell Death and Differentiation
- 6 July 2007
Lipodystrophic syndromes associated with mutations in LMNA, encoding A-type lamins, and with HIV antiretroviral treatments share several clinical characteristics. Nuclear alterations and prelamin A… Expand
Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
- M. Diamant, L. V. Van Gaal, +5 authors M. Trautmann
- The lancet. Diabetes & endocrinology
- 1 June 2014
BACKGROUND When patients with type 2 diabetes start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 (GLP-1) receptor agonists and basal insulins. In DURATION-3,… Expand
Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
- R. S. Weinstock, B. Guerci, G. Umpierrez, M. Nauck, Z. Skrivanek, Z. Milicevic
- Diabetes, obesity & metabolism
- 20 May 2015
To compare the once‐weekly glucagon‐like peptide‐1 (GLP‐1) receptor dulaglutide with the dipeptidyl peptidase‐4 (DPP‐4) inhibitor sitagliptin after 104 weeks of treatment.
The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients.
OBJECTIVE This study was designed to assess the insulin-sparing effect of oral administration of metformin along with a continuous subcutaneous insulin infusion (CSII) for the treatment of type 1… Expand
New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome.
- A. Decaudain, M. Vantyghem, +11 authors C. Vigouroux
- The Journal of clinical endocrinology and…
- 1 December 2007
CONTEXT Mutations in the LMNA gene are responsible for several laminopathies, including lipodystrophies, with complex genotype/phenotype relationships. OBJECTIVE, DESIGN, SETTING, AND PATIENTS:… Expand
Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1…
OBJECTIVE This study was designed to test the accuracy of capillary ketonemia for diagnosis of ketosis after interruption of insulin infusion. RESEARCH DESIGN AND METHODS A total of 18 patients… Expand